Navigation Links
Sinobiopharma Applies For Two Chinese Patents For Cisatracurium Besylate
Date:5/21/2009

NANJING, China, May 21 /PRNewswire-FirstCall/ -- Sinobiopharma Inc. ("Sinobiopharma ", or "the Company") (OTC Bulletin Board: SNBP) is pleased to announce that it has applied for two Chinese patents for its flagship product, Cisatracurim besylate, a pre-surgical skeletal muscle relaxant.

The Company has applied to China's State Intellectual Property Office (SIPO) for a Chinese patent for Atracurium's freeze-drying compounds (Application Number 200710127756.2; "Atracurium's freeze-drying compounds"). This patent has already been published and is now awaiting certification.

The Company has also applied to SIPO for a Chinese patent for the preparation for separating and purifying Cisatracurim besylate through HPLC (Application Number 200910028198.3; "The preparation for separating and purifying Cisatracurim besylate through HPLC"). Using this method, the Company will reduce manufacturing costs and improve product quality.

About Sinobiopharma

Sinobiopharma, Inc. is a fully integrated and highly innovative biotechnology company engaged in the research and development, manufacture and marketing of biopharmaceutical products in China, the world's fastest growing pharmaceutical market. Known as Dong Ying (Jiangsu) Pharmaceutical Co. Ltd. in China, the Company's current therapeutic focus is on anesthesia-assisted agents and cardiovascular drugs.

FORWARD LOOKING STATEMENTS

This news release may include "forward-looking statements" regarding Sinobiopharma, Inc., and its subsidiaries, business and project plans. Such forward looking statements are within the meaning of Section 27A of the Securities Act of 1933, as amended, and section 21E of the United States Securities and Exchange Act of 1934, as amended, and are intended to be covered by the safe harbor created by such sections. Where Sinobiopharma, Inc. expresses or implies an expectation or belief as to future events or results, such expectation or belief is believed to have a reasonable basis. However, forward-looking statements are subject to risks, uncertainties and other factors, which could cause actual results to differ materially from future results expressed, projected or implied by such forward-looking statements. Sinobiopharma, Inc. does not undertake any obligation to update any forward-looking statement, except as required under applicable law.


'/>"/>
SOURCE Sinobiopharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Sinobiopharma Updates on Progress; Projects Increases in Sales and Revenues In 2009
2. Sinobiopharma Announces SFDA Approval of Anti-Hypertension Drug Perindopril
3. Sinobiopharma Secures Rights to Seven Key Patents
4. Sinobiopharma Reports a 141% Increase in Revenues From Unaudited Financial Results for the 9 Month Period Ended February 28, 2009
5. Sinobiopharma Reports a 41% Increase in Revenues From Unaudited Financial Results for the 9 Month Period Ended February 28, 2009
6. Sinobiopharma, Inc. Appoints New Director of Marketing
7. Sinobiopharma Signs Export Agreement With U.S. Pharmaceutical Supplier
8. Sinobiopharma Reports Financial Highlights for Six-Month Period Ending November 30, 2008
9. iCardiac Applies Advanced Cardiac Safety Biomarkers in Clinical Study for Top Pharmaceutical Company
10. Tissue Genesis Applies CE Mark to Its Adult Stem Cell Isolation System
11. Saddam Lawyer Applies for Pardon for Dr Crippen
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)... Feb. 12, 2016 Biocom, the association representing the ... a group of San Diego companies ... its 2016 Precision Medicine Advocacy Fly-In. Biocom Fly-In participants had ... Drug Administration (FDA), the Centers for Medicare and Medicaid Services ... San Diego U.S. Representatives Susan Davis and ...
(Date:2/12/2016)... 12, 2016  PTC Therapeutics, Inc. (NASDAQ: ... (Strategies to Realize Innovation, Vision and Empowerment) grant ... provides funds to patient advocacy organizations to develop ... contributions to the rare disease community by increasing ... patient advocates. Mary Frances Harmon ...
(Date:2/11/2016)... -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX ) today announced its financial ... --> --> For the fourth ... million, or $0.34 loss per share, compared to a net loss ... period in 2014. For the year ended December 31, 2015, the ... per share, as compared to a net loss of $60.5 million, ...
(Date:2/11/2016)... -- Bioethics International, a not-for-profit organization focused on the ethics and ... accessible to patients around the world, today announced that the ... of the Good Pharma Scorecard an ,Editors, ... one of BMJ Open ,s ,Most Popular Articles, which ... frequently read. Ed Sucksmith , assistant editor of ...
Breaking Biology Technology:
(Date:1/20/2016)... Jan. 20, 2016   MedNet Solutions , an ... spectrum of clinical research, is pleased to announce the ... achievements are the result of the company,s laser focus ... eClinical , it,s comprehensive, easy-to-use and highly affordable ... --> Key MedNet growth achievements in 2015 include: ...
(Date:1/18/2016)... JOSE, Calif. , Jan. 18, 2016 /PRNewswire/ ... security software that simplifies the use and access ... technology and go-to-market partnership with American Cyber.  ... Cyber brings extensive experience leading transformational C4ISR and ... implementing and integrating the latest proven technology solutions," ...
(Date:1/13/2016)... --> --> ... report titled - Biometric Sensors Market - Global Industry Analysis, ... to the report, the global biometric sensors market was valued at ... US$1,625.8 mn by 2023, expanding at a CAGR of ... the biometric sensors market is expected to reach 1,799.6 ...
Breaking Biology News(10 mins):